Stage III Breast Cancer Recruiting Phase 3 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0031775 (Stage III Breast Cancer)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02954874Pembrolizumab in Treating Patients With Triple-Negative Breast CancerTreatment